Viatris Raised 2026 Guidance-But Is 11% Down From Fair Value Really a Margin of Safety?

Raising guidance matters more than the headline discount

Viatris still trades at roughly a 11% discount to fair value, but that gap is no longer the whole story. The more important shift is that the company moved from saying a turnaround was possible to showing operating progress. On Aug. 6, Viatris said it was raising 2026 financial guidance midpoints for all metrics after posting 3.5% operational revenue growth in the second quarter. That changes the debate from whether execution is improving to whether the market is giving enough credit for that improvement.

What changed in the latest quarter

The quarter strengthened the execution case on several fronts at once. Viatris said it had approximately $550 million of capital to shareholders, including through share repurchases and reduced its gross leverage ratio to 2.9x. It also said it was raising 2026 financial guidance midpoints for all metrics. When growth, balance-sheet improvement, and shareholder returns appear in the same report, the story stops looking theoretical.

Why the next move is mostly perceptual

The remaining question is not whether Viatris is executing. It is whether investors will reprice the company faster than management continues to post decent results. If that is right, the next upside may come less from a dramatic change in the numbers and more from the market assigning a more favorable lens to those numbers.

Viatris may be moving beyond a plain-vanilla generics label

The key issue is no longer simple execution. It is what kind of business is executing.

The portfolio mix is becoming harder to dismiss

A generics-only company is usually judged mainly on price pressure and commodity-style margins. Viatris, however, has been describing a different mix. At its March investor event, the company said its base business is evolving into a more durable portfolio of higher-margin generics, value-added medicines and established brands. That matters because investors typically discount recurring, brand-supported cash flows differently from purely price-sensitive generics revenue.

That shift is happening alongside scale and growth that are still meaningful. Viatris reported $14.3 billion of 2025 revenue, and in the first quarter of 2026 it reported 8% reported growth alongside 10% operational EBITDA growth. The fact that earnings grew faster than revenue supports the idea that operating leverage is improving.

Launches are the next real test of the re-rating thesis

Near-term launches matter because they can change how investors categorize the business. Viatris pointed to expecting impactful near-term launches, including fast-acting meloxicam and low-dose estrogen weekly patch in the U.S., and pitolisant and Effexor for GAD in Japan. Those launches matter not just for revenue, but for perception: can Viatris successfully commercialize products outside its legacy comfort zone and build a more diversified growth profile?

That is the real divide between bulls and bears. Bulls see a company gradually earning a different label. Bears see the market still anchoring to Viatris' older generics identity. For now, the evidence suggests the mix story is becoming harder to ignore.

Cash and capital returns widen the case for waiting less

Viatris also returned more than $1 billion to shareholders in 2025 and said it expects $650 million in total cost savings with reinvestment of up to $250 million over the next three years. Separately, management said it expects more than $2.5 billion of cash available for deployment in 2026. At a broader planning level, the company also said it expects more than $11 billion in cash available for deployment through 2030.

That matters because cash gives management more ways to improve the quality of growth, support buybacks, or fund accretive moves. The risk is straightforward: if launches disappoint or savings fail to translate into growth, investors will go back to judging Viatris mainly as a generics business. For now, though, the setup looks less like a fragile turnaround story and more like an early portfolio re-rating story.